This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.83% per year. These returns cover a period from January 1, 1988 through January 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
coronavirus: Archive
Pandemic Stock Winners Shopify, Peloton and Zoom: Buying Opportunities in 2025?
by Tracey Ryniec
These stocks hit new highs in 2021 but sold off in the 2022 plunge. Should they be on your watch list in 2025?
SHOPNegative Net Change ZMPositive Net Change PTONPositive Net Change
coronavirus stock-performance
Buy Pfizer (PFE) Stock for a Rebound After Crushing Q1 EPS Expectations?
by Shaun Pruitt
Pfizer (PFE) shares spiked 3% in Tuesday's trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations.
PFEPositive Net Change JNJPositive Net Change NVOPositive Net Change LLYNegative Net Change ABBVPositive Net Change
coronavirus dividend-investing dividends earnings investing medical pharmaceuticals vaccines
Uber: Dominating Ride-Sharing and Delivery
by Andrew Rocco
Uber Technologies has morphed into a fundamental market leader with consistent profitability. In today's commentary, Stock Strategist Andrew Rocco profiles the ride-sharing leader.
DALNegative Net Change DPZPositive Net Change COSTNegative Net Change GOOGLPositive Net Change CARTPositive Net Change LYFTPositive Net Change UBERNegative Net Change DASHPositive Net Change
autonomous-vehicles coronavirus ride-hailing self-driving-cars
Pharmaceutical Stocks Hit New Highs Amid Market Volatility
by Bryan Hayes
During this time of heightened market volatility, it pays to be invested in the right places.
GILDPositive Net Change
cancer cell-therapy coronavirus earnings immuno-therapy investing medical oncology-screening vaccines
Why Novavax is Gaining Ground in COVID-19 Vaccine Race
by Andrew Rocco
Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the stock offers the best reward prospects in the industry.
SNYPositive Net Change PFEPositive Net Change MRNANegative Net Change NVAXPositive Net Change
coronavirus vaccines
Where are the Pandemic Winners Now? ZM, SHOP, PTON
by Derek Lewis
While stay-at-home stocks were all widely hailed during 2020 and 2021, their performance since then has primarily left a sour taste in investors' mouths. Is it time to revisit them?
SHOPNegative Net Change ZMPositive Net Change PTONPositive Net Change
business-services coronavirus e-commerce tech-stocks
WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch
by Andrew Rocco
Is the next pandemic here. With health officials declaring Monkeypox a public health emergency, investors need to be watching Monkeypox-related stocks.
TNXPNegative Net Change EBSNegative Net Change GOVXNegative Net Change VRAXPositive Net Change
biotechnology biotechs coronavirus vaccines
Bull of the Day: DoorDash (DASH)
by Andrew Rocco
DoorDash stands out as a leader in the food delivery service industry. The company's strategic expansion beyond traditional partnerships will spur revenue growth. Furthermore, the "new economy" will benefit the company for years to come.
BIGPositive Net Change DKSNegative Net Change SFMPositive Net Change GONegative Net Change DASHPositive Net Change
coronavirus earnings mobile software
Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?
by Shaun Pruitt
Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.
AZNPositive Net Change PFEPositive Net Change MRNANegative Net Change
biotechnology cancer cell-therapy coronavirus earnings gene-therapy immuno-therapy investing medical messenger-rna pharmaceuticals vaccines
Stocks on the Mend: A Mean Reversion Duo
by Andrew Rocco
September is starting in classic, historically weak form. However, if the market finds it's footing, two stocks have explosive, reversion to the mean potential.
AMDNegative Net Change JNJPositive Net Change PFEPositive Net Change MRNANegative Net Change NVAXPositive Net Change QQQPositive Net Change
biotechnology biotechs coronavirus investing semiconductor vaccines